Kornimate/medical-research-clean huggingface dataset:
dhea supplementation for low ovarian response ivf patients

Conditions: Infertility, Female; In-Vitro Fertilization

Summary: approximately 10% of all couples will be diagnosed as infertile. the most efficient infertility treatment is in-vitro fertilization (ivf). one major determinant for success is production of an adequate number of oocytes (eggs) from the female in order to finally have good-quality embryos and finally acceptable pregnancy and delivery rates. some women will not respond adequately to hormonal stimulation and will only a small number of oocytes. therefore, the chances of finally having a successful delivery are significantly reduced. although the specific definition of this situation is controversial, these patients are diagnosed as having "low ovarian response". this condition is more prevalent in older ivf patients as part of the reproductive aging process; it is possible at any age. currently, the understanding of "low ovarian response" is limited, and although many therapeutic approaches have been suggested, no treatment has been proven significantly efficient. dhea is a pro-hormone produced by the adrenal gland and the ovary. dhea serum levels become lower with age and in some chronic diseases. therefore, some believe it may be beneficial as an 'anti-aging' factor. dhea pills are available as a food-supplement, without need for prescription in the us. dhea is involved in the regulation of follicular growth in the ovaries. in a 2000 report, five ivf patients who had low ovarian response were treated with oral dhea (casson et al, hum reprod 2000;15:2129). a small increase in the ovarian response to hormonal stimulation was noticed. barad and gleicher reported their relatively extensive experience, summarizing treatment outcome in 25 ivf low-responders treated with oral dhea pills (barad and gleicher, hum reprod 2006; 21, 2845). they observed increased increases in fertilized oocytes, normal day 3 embryos, and number of embryos transferred after dhea treatment compared with a previous treatment outcome before dhea. based on this observation, dhea may appear useful for improving ivf outcome in some patients. however, a prospective randomized study on dhea supplementation for ivf patients was not yet published. our aim is to conduct such a study, focusing on ivf patient with low ovarian response.


Eligibility criteria:
inclusion criteria: * ivf patient * low ovarian response to hormonal stimulation exclusion criteria: * previous dhea supplementation * history of malignant disease * liver dysfunction * coagulation tendency

Keywords: dhea ivf low ovarian response
aml/mds drug sensitization by in vivo chemotherapy administration

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes

Summary: in this study, the investigators will explore the feasibility of ex vivo drug screening to predict sensitivity to chemotherapy resistance and to identify novel synergy between chemotherapies.


Eligibility criteria:
inclusion criteria: * acute myeloid leukemia (aml) or myelodysplastic syndrome (mds) * peripheral blood blasts \> 1% * peripheral white blood cell count \> 1,000/µl. * age ≥ 18 years * anticipated treatment with any of the following regimens (cohort 0) or: * cohort 1: a standard induction protocol with infusional cytarabine * cohort 2: decitabine (either 5-day or 10-day regimens) * cohort 3: azacitidine (either intravenous or subcutaneous administration) * cohort 4: decitabine (either 5-day or 10-day) + venetoclax * cohort 5: azacitidine (either intravenous or subcutaneous administration on 7 day or 5+2+2 schedule) + venetoclax * patients may receive these therapies as part of other on-going clinical trials or as standard of care treatment. * patients in cohort 1 may receive soc midostaurin or gemtuzumab ozogamicin, provided these start after the day 2 sample is collected. patients in cohort 1 may receive a standard combination of cytarabine/idarubicin, cytarabine/daunorubicin, or vyxeos, a liposomal formulation of cytarabine and daunorubicin. * ecog performance status ≤ 3 * ability to understand and willingness to sign an irb approved written informed consent document. exclusion criteria: * pregnant or currently nursing * prior chemotherapy with hypomethylating agents * known history of positive hiv serology. * known positive hepatitis c serology. * patient must not have received any chemotherapy within 7 days of enrollment, and any acute treatment-related toxicities must have returned to baseline. patients may have received hydrea as long as they fulfill peripheral blood blast and peripheral wbc inclusion criteria. prior tki therapy is allowed, but must be discontinued within 3 days of baseline blood collection. * currently receiving any other investigational agents.
high frequency chest wall oscillations versus lung flute in chronic obstructive pulmonary disease post(sars-cov-2)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: copd causes an acute deterioration of respiratory symptoms, particularly increased breathlessness and cough, and increased sputum volume and/or purulence. worsening airflow limitation is associated with an increasing prevalence of exacerbations and risk of death. these exacerbations can range from self-limited diseases to episodes of florid respiratory failure requiring mechanical ventilation .hospitalization for copd patients post covid is associated with poor prognosis with increased risk of death. hence techniques of efficient clearance of peripheral airways may reduce airway occlusion by excess mucus and inflammatory cells, improving lung function, exercise capacity and reducing exacerbation frequency.

patients were assigned to 2 groups with pre- and post- treatment protocol application. all patients were thoroughly evaluated before and after treatment protocol application. thirty patients (group a) received high frequency chest wall oscillation with vest system in addition to their prescribed medication, 3 times per week for three successive weeks and the total duration of each session was 15-30 minutes. thirty patients (group b) received lung flute (opep) in addition to their prescribed medication, 2 times per week twice a day for three successive weeks and the total duration of each session was 10-15 minutes

Eligibility criteria:
inclusion criteria: * all patients aged 40-60 years old * all patients were recovered from covid not more than 3 months * all patients were diagnosed as copd for at least two years ago. * all patients had irreversible/ partially reversible obstruction of airflow. * copd patients had a post-bronchodilator, fev1/fvc% \< 70%. they had an increase in fev1\< 200 ml, or \< 12% of baseline value 20 minutes after 2 puffs of inhaled salbutamol (100 µg) given via a metered-dose inhaler. exclusion criteria: * presence of malignant disease. * patients with acute infection. * history of osteoporosis, significant gastro-oesophageal reflux, hiatus hernia. * recent acute cardiac event (6 weeks) or congestive cardiac failure. * any significant musculoskeletal disorders.
thermogenesis in hyperthyroidism and effect of anti-adrenergic therapy

Conditions: Hyperthyroidism

Summary: the overall objective of the heat study is to determine the acute effect of propranolol on energy expenditure in patients suffering from hyperthyroidism and to evaluate the consequences of the change of hyper- to euthyroidism on metabolism during the course of treatment, especially with regard to the reaction to cold ambient temperatures.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * age 18 to 70 years * hyperthyroidism: thyroid-stimulating hormone (tsh) below 0.2 mu and free t4 at or above 25 pmol/l or free t3 at or above 8 pmol/l. exclusion criteria: * contraindications to propranolol: hypersensitivity or allergy * therapy with a beta blocker for reasons other than hyperthyroidism (e.g. cardiac arrhythmia or heart failure) * treatment with amiodarone * women who are pregnant or breast feeding, * intention to become pregnant during the course of the study, * history of asthma or chronic obstructive pulmonary disease * occlusive peripheral artery disease; raynaud's syndrome. * other clinically significant concomitant disease states: * known renal failure (gfr \< 50 ml/min) * known hepatic dysfunction * known heart failure or unstable angina pectoris * known or suspected non-compliance, drug or alcohol abuse, * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant, * participation in another study with investigational drug within the 30 days preceding and during the present study, * previous enrolment into the current study, * enrolment of the investigator, his/her family members, employees and other dependent persons. * ecg-criteria * resting heart rate below 60 bpm * complete left bundle branch block * atrioventricular block (av-block) grade 2 or 3

Keywords: brown adipose tissue (bat) hyperthyroidism
mepolizumab for the treatment of chronic spontaneous urticaria

Conditions: Chronic Spontaneous Urticaria

Summary: this is an exploratory study designed to generate preliminary data in evaluating the efficacy of nucala in the treatment of chronic spontaneous urticaria.

this is an open-label, single arm exploratory study of mepolizumab in the treatment of csu. the primary endpoint will be the mean reduction in the seven day urticaria activity score (uas7) before and after 10 weeks of treatment with mepolizumab. secondary endpoints will be the mean reduction of the urticaria control test (uct) score and the weekly itch severity score (iss) before and after treatment. enrollment examination will include a standardized history and examination, baseline uct score, cbc with differential, serum ige level, chronic urticaria index, ige fc receptor antibody functional assay, and a 4 mm punch biopsy of lesional skin to confirm the urticarial tissue reaction includes eosinophils and is not neutrophilic predominant. patients will discontinue all anti-histamines and start cetirizine 10 mg po bid which may be continued throughout the study duration. patients will be provided with a log book to track daily urticaria signs and symptoms in a standardized manner for uas scoring. at week 0 (enrollment visit +7 days), baseline uas7 and iss score will be assessed and skin biopsy results reviewed. patients with a confirmatory skin biopsy will receive 200 mg sc of mepolizumab at week 0,2,4,6,and 8. uas-7 and weekly iss score will be calculated at week 0, 4, 8, and 10. uct scoring will be calculated at week 0 and at week 10. repeat cbc with differential, serum ige level, and measures of basophil serum activation (chronic urticaria index, ige fc receptor antibody functional assay) will be assessed at week 10. attached to this document is a protocol summary.

Eligibility criteria:
inclusion criteria: * male and female patients 18 years or older. * clinical and/or histopathological diagnosis of conventional csu * unresponsive to oral antihistamine therapy * good general health as confirmed by medical history * patients who are willing and capable of cooperating to the extent and degree required by the protocol; and * patients who read and sign an approved informed consent for this study exclusion criteria: * vulnerable study population * pregnant or nursing women * women planning a pregnancy within the study period * current or previous xolair use * biopsy proven neutrophilic rich urticaria * known history of adverse reaction to nucala * severe asthma requiring high-dose inhaled or systemic corticosteroids
prospective clinical and biologic study of secondary cutaneous effects in targeted cancer therapies

Conditions: Cancer

Summary: the aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.


Eligibility criteria:
inclusion criteria: * patients with cancer beginning a targeted therapy * patients able to follow the protocol * age \>/= 18 years old * signed inform consent exclusion criteria: * patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study * pregnant or breastfeeding woman
capa in-vitro oocyte maturation

Conditions: Infertility, Female

Summary: in vitro oocyte maturation (ivm) is a mild-approach assisted reproductive technology (art). because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of ivm compared to controlled ovarian stimulation (cos) in polycystic ovary syndrome (pcos) patients, the use of ivm in selected patients may gain increasing interest. besides its application in patients with polycystic ovaries, ivm technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.


Eligibility criteria:
inclusion criteria: * patients aged from 0-50 years old * patients seek fertility preservation services * patients seek oocyte retrieval services exclusion criteria: -patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Keywords: in vitro oocyte maturation techniques
evaluation the preoperative anxiety level of the surgeons

Conditions: Preoperative Anxiety

Summary: many studies are present about the preoperative anxiety among patients. but the preoperative anxiety of the surgeons is not studied yet. the aim of this study is to evaluate the preoperative anxiety of the surgeons.100 surgeons consisted of performing operations in general surgery, obstetric and gynecology , orthopedic surgery ,ophthalmology, otorhinolaryngology, plastic and reconstructive surgery, urology, gynecologic oncology, surgical oncology, cardiovascular surgery, pediatric surgery and neurosurgery will be participated in the study. surgeons will be chosen from the specialist doctor, assistant doctor, doctor lecturer, associate professor and professors.15 minutes prior to the first elective operation of the day, salivary cortisol samples will be taken from the surgeons and they will be asked to fill the evaluation form and state-trait anxiety inventory form (stai).

100 surgeons between the ages of 25-55 years will be participated in the study. surgeons will be consisted of performing operations in general surgery, obstetric and gynecology, orthopedic surgery, ophthalmology, otorhinolaryngology, plastic and reconstructive surgery, urology, gynecologic oncology, surgical oncology, cardiovascular surgery, pediatric surgery and neurosurgery.they will be chosen from the specialist doctor, assistant doctor, doctor lecturer, associate professor and professors. oral and written informed consent will be obtained from the surgeons.15 minutes prior to the first elective operation of the day salivary cortisol samples will be taken from the surgeons and they will be asked to fill the evaluation form and state-trait anxiety inventory form (stai). the evaluation form will include the age, gender of the surgeon, surgical department, academic superscription, years of clinical experience in medical sciences and professions and the name of the surgery which is going to be done.

Eligibility criteria:
inclusion criteria: * accepting to participate the study * surgeons planning first elective operation of the day * 25-55 years exclusion criteria: * non volunteers * neurological and psychological disorders * history of anxiolytic , antidepressant drug usage

Keywords: surgeon cortisol anxiety
a randomized control trial of patient-initiated hospital follow-up for patients with psoriasis

Conditions: Psoriasis

Summary: the primary objective of this research protocol is to evaluate the health related quality of life and efficacy of patient-initiated hospital follow-up for patients with moderate to severe psoriasis.

psoriasis is a chronic inflammatory skin disease affecting 1 to 3% of the european population. treatment of moderate to severe psoriasis often requires lifetime routine reviews by hospital dermatologist. patterns of hospital review vary, but most patients attend follow-up every 12-16 week by dermatologist. at routine reviews the patient disease is often quiet and little intervention or no intervention is required, and times were the patient need help the time is limited for in-depth consultation. both patient and healthcare professional requested more time. in-depth consultation is important in the care of psoriasis, because moderate to severe psoriasis has a significant impact on quality of life and patient have an increased incidence of cardiovascular risk factors such as hypertension, overweight, hyperlipidemia and exposure to tobacco and alcohol. these comorbidities and the psychosocial burden must be addressed by clinicians to help patients to acquire or to maintain competencies that are required to live with a chronic disease. patient-initiated hospital follow-up for patients with moderate to severe psoriasis might reduce inappropriate follow-up appointments, improve rapid access to specialist care and release resource to further in-depth consultation. if the patient is empowered to initiate hospital review thus patient's individual needs dictate the content, duration and contact with clinicians. it is our goal that an individual needs-based patient involvement in the shape of patient-initiated hospital follow-up,will be perceived as a benefit of the patients who 1) meets a high safety in the patient's own provision of medical treatment, 2) increase the patient's knowledge of the lifestyle and prevention of comorbidities and 3) strengths patient's overall satisfaction with treatment.

Eligibility criteria:
inclusion criteria: • patients in stable systemic psoriasis treatment defined as having received treatment for more then 12 weeks without complication and being adherence to medication administration. exclusion criteria: * patients not able to give informed consent * patients not able to follow the program * patient with server psychiatric diseases
tissue bank of biological specimens from patients with gynecologic disease

Conditions: Endometrial Neoplasms; Uterine Cervical Neoplasms; Ovarian Neoplasms; Leiomyoma

Summary: the purpose of this study is to create a tissue bank of gynecologic cancers and normal tissue for the study of cancer in order to better understand the changes occurring on a molecular level (dna, rna, protein) that lead to the development of cancer.

cancer arises due to genetic alterations that disrupt numerous cellular functions including proliferation, programmed cell death and senescence, that ultimately control the number of cells in a population. the genetic damage that underlies the development of cancers has a diverse etiology and loss of dna repair mechanisms also may play a role in allowing mutations to accumulate. cancers are also characterized by the ability to invade surrounding tissues and to metastasize. many of the molecular alterations involved in this process have yet to be elucidated. gynecologic cancers afflict women of all ages. cervical cancer is the most common gynecologic malignancy worldwide, accounting for over 400,000 cases annually. endometrial cancer is the most common gynecologic malignancy with approximately 33,000 new cases being diagnosed annually in american women. ovarian cancer is the fourth most common cause of cancer related mortality in american women, with approximately 14,000 deaths occurring from it in 2000. the creation of a tissue repository containing tissue specimens, blood/serum, and molecular extracts (dna, rna, protein) will provide a rich source of tissue for future gynecological disease research studies.

Eligibility criteria:
inclusion criteria: * patients scheduled to undergo surgery for diagnosis and treatment of a gynecologic disease at one of the participating institutions * \> = 18 years old * ability to read english exclusion criteria: * \< 18 years old

Keywords: tissue bank endometrial neoplasm uterine cervical neoplasm ovarian neoplasm leiomyoma dna rna protein serum
adjuvant study of pyrotinib in combination with trastuzumab in her2 positive invasive breast cancer

Conditions: Breast Cancer

Summary: this is an open label, phase iii study evaluating the efficacy and safety of pyrotinib in combination with trastuzumab and paclitaxel in patients her2 positive and lymph node negative invasive breast cancer


Eligibility criteria:
inclusion criteria: * females 18-70 years old; * pathological confirmed of stage i-ii breast cancer: histologically confirmed that the longest diameter of invasive cancer is no less than 1cm and no more than 5cm and the lymph node is negative (n0); * the pathological type of immunohistochemistry must meet the following conditions: her-2 (3+) or her-2 (0-2 +) with fish detection is amplified; * for patients with invasive lesions on both sides, if both lesions are her-2 positive and meet the tumor size requirements, then can be enrolled; * has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin ≥ 90 g/l (no blood transfusion within 14 days); absolute neutrophil count ≥ 1.5 x 109 /l; platelet count ≥ 100 \* 109 /l; (2)adequate liver and kidney function: alanine aminotransferase (alt) ≤ 3×upper limit of normal (uln), aspartate aminotransferase (ast) ≤ 3×uln, total bilirubin (tbil)≤ 1.5×uln, serum creatinine ≤ 1×uln#and with endogenous creatinine clearance rate of \>50 ml/min (cockcroft-gault formula); * lvef\>50%; * the patient voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up. exclusion criteria: * has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy; * has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ; * has metastic (stage 4) breast cancer; * pregnant or breast feeding women, or women of childbearing age who cannot practice effective contraceptives; * patients participating in other clinical trials at the same time; * has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (lvef) \ 150/90mmhg, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; * has severe or uncontrolled infection; * has a history of psychotropic substance abuse and were unable to abandon drug habits, or those with history of mental disorders; * the researchers considered patients to be unsuitable for the study.